Ascenta Therapeutics cements treatment potential of AT-101
Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel (Taxotere) and prednisone in men with docetaxel refractory, castrate resistant prostate cancer (CRPC). AT-101 is an oral, pan-Bcl-2 inhibitor.
Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel (Taxotere) and prednisone in men with docetaxel refractory, castrate resistant prostate cancer (CRPC). AT-101 is an oral, pan-Bcl-2 inhibitor.
Initial findings from the ongoing open-label, multicenter study demonstrated that AT-101 can be administered safely with docetaxel and prednisone in these patients. Results were released at the 2009 ASCO GU Cancers Symposium in Orlando, Fla. The analysis included data from 37 men with docetaxel-refractory CRPC who were treated with docetaxal (75 mg/m2 q3 weeks), prednisone (5 mg b.i.d. on days 1-21) and AT-101 (40 mg b.i.d. on days 1-3 of each 21-day cycle).
Thirty-eight percent of patients treated had at least a 30% decrease in PSA level and 19% achieved a confirmed partial response.
Investigators also observed clinical responses, based on both PSA and RECIST criteria, including four patients with a confirmed partial response, defined as a PSA decline of 50% or greater.
The most common adverse events included fatigue (50%) and diarrhea (27%), as well as nausea, anorexia, and neutropenia (all 23%).
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
